Irbesartan Pentafarma

Irbesartan, the active ingredient in Irbesartan Pentafarma, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is prescribed to lower high blood pressure and to protect kidney function in adult patients with diabetic nephropathy.

GNH USA supplies Irbesartan Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU‑GMP standards and providing reliable sourcing for cardiovascular and renal therapeutic programs, with a focus on consistent quality, traceability and on‑time delivery to meet the demands of global healthcare providers.

Irbesartan is employed to treat conditions that involve the renin‑angiotensin system, primarily high blood pressure and kidney disease linked to diabetes.

- Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of cardiovascular events in patients with elevated arterial pressure. - Diabetic nephropathy: decreases proteinuria and slows the progression of renal impairment in individuals with type 2 diabetes. - Chronic kidney disease: helps control blood pressure and provides renal protective effects in patients with non‑diabetic chronic kidney disease.

Irbesartan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection - Diarrhea - Hyperkalemia

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute renal failure - Hepatic injury - Myocardial infarction - Neutropenia

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure patient safety.

- Monitor blood pressure: check regularly to avoid excessive hypotension. - Assess renal function: evaluate serum creatinine and eGFR before and during therapy. - Check serum potassium: hyperkalemia risk requires periodic potassium monitoring. - Use caution in severe hepatic impairment: dose adjustment may be needed. - Avoid use during pregnancy: potential fetal toxicity; discontinue if pregnancy is detected. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Irbesartan can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - ACE inhibitors: concurrent therapy heightens risk of angioedema and renal impairment. - NSAIDs (high‑dose): can reduce antihypertensive effect and impair renal function. - Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect may require dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma levels, necessitating monitoring.